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Abstract 
Background: Most metastatic gastrointestinal stromal tumors (GISTs) develop resistance to 
the first line imatinib treatment. Recently, increased vessel density and angiogenic markers 
were reported in GISTs with worse prognosis, suggesting the angiogenesis implication in 
GIST tumor progression and resistance. The purpose of this study is to investigate the 
relationship between tumor vasculature and imatinib resistance in different GIST mouse 
models by a non-invasive magnetic resonance imaging (MRI) functional approach.  
Methods: Immunodeficient mice (n=8 for each cell line) were grafted with imatinib-sensitive 
(GIST882 and GIST-T1) and resistant (GIST430) human cell lines. Dynamic contrast-
enhanced MRI (DCE-MRI) were performed on GIST xenografts to quantify tumor vessel 
permeability (Ktrans) and vascular volume fraction (vp). Microvessel density (MVD), 
permeability (mean dextran density, MDD) and angiogenic markers were evaluated by 
immunofluorescence and western blot assays. 
Results: DCE-MRI showed significantly increased vessel density (p<0.0001) and 
permeability (p=0.0002) in imatinib-resistant tumors compared to imatinib-sensitive ones. 
Strong positive correlation is observed between MRI estimates, Ktrans and vp, and their related 
ex-vivo values, MVD (r=0.78 for Ktrans and r=0.82 for vp) and MDD (r=0.77 for Ktrans and 
r=0.94 for vp). In addition, higher expression of vascular endothelial growth factor receptors 
(VEGFR2 and VEFGR3) is shown in GIST430.  
Conclusions: DCE-MRI highlights marked differences in tumor vasculature and 
microenvironment properties between imatinib-resistant and sensitive GISTs, confirmed by 
ex-vivo assays. These results provide new insights in the role that DCE-MRI may play for 
GIST characterization and response to treatment. Validation studies are warranted to confirm 
these findings and determine potential implications. 
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Miniabstract 
DCE-MRI detects significant increased vascularity and vessel permeability in imatinib-
resistant GIST tumors in comparison to sensitive ones. Therefore, 
vascularization/permeability properties could be investigated as GIST biomarkers of therapy 
response. 
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Introduction 
Gastrointestinal stromal tumor (GIST) is the most common malignant mesenchymal 
neoplasm of the digestive tract, with a mean annual incidence of 11-14 patients per million 
people. Surgical resection is the first line treatment for localized or resectable GISTs. 
However, every GIST is considered to be potentially malignant and metastases are observed 
in liver or peritoneal cavity in 50% of cases following primary surgical resection [1, 2]. GISTs 
are commonly distinguished from other sarcomas by gain-of-function mutations of the 
tyrosine kinase KIT receptor [3]. Imatinib (Gleevec; Novartis Pharmaceuticals) is a potent 
inhibitor of KIT and is currently the only effective treatment against metastatic and 
unresectable GIST [4-7]. However, clinical data highlight imatinib failure in the complete 
eradication of the disease since most of patients develop resistance after few months of 
treatment, with significant complications in the follow-up studies [8, 9].  
Particular issues rely on the evaluation of GIST prognosis along transformation from benign 
to malignant tumor. The Fletcher classification system easily allows accurate stratification of 
GIST patients assessing tumor size, mitotic count and anatomic location [10]. Moreover, 
recent studies demonstrated the prognostic significance of some molecular markers, as the 
proliferating cell nuclear antigen Ki-67 and the KIT mutational status [11, 12]. However, the 
evaluation of most of these GIST signatures can be performed only after surgical resection of 
the whole tumor or can be biased by the limited sampling of biopsies, with evident obstacles 
of prognosis for inoperable GISTs. 
Notably, several investigations have introduced ex-vivo the association of vascularization 
and angiogenic markers with GISTs presenting the worst prognosis [13-16]. Considering the 
prognostic role of angiogenesis in GIST, the identification of reliable non-invasive tools able 
to monitor tumor vascularization may provide new insight in GIST characterization and 
therapy response evaluation. Solid tumors typically display altered and unstructured 
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vasculature responsible of irregular perfusion and permeability [17] and these properties can 
be assessed by several imaging approaches that allow the visualization of intratumoral 
vessels [18, 19]. Among them, the dynamic contrast-enhanced magnetic resonance imaging 
(DCE-MRI) approach offers the unique advantage of combining high spatial resolution and 
tissue contrast with functional information [20]. Following the injection of a paramagnetic 
contrast agent (CA), it is possible to evaluate the tissue contrast enhancement produced by 
its extravasation through hyperpermeable tumor vessels and extrapolate pharmacokinetic 
parameters informative of vascular permeability and perfusion (Ktrans), extracellular volume 
fraction (ve), and blood plasma volume fraction (vp) [21, 22]. DCE-MRI has proven to be a 
promising tool for the assessment of malignancy in different cancers and the obtained kinetic 
constants can be exploited as biomarkers to assess tumor angiogenesis and response to 
antiangiogenic therapy [23-27].  
We therefore hypothesized that quantitative permeability measurements might reveal 
characteristic vascularization properties between imatinib sensitive and resistant GIST 
tumors. This assumption is supported by studies assessing perfusion in GIST tumors by 
exploiting contrast enhanced ultrasonography and computed tomography [28, 29]. For this 
purpose, three mouse models of imatinib-sensitive and resistant tumors on highly 
immunodeficient NOD scid gamma (NSG) mice were used. Functional MRI was exploited to 
characterize tumor microenvironment in terms of vascularization and permeability by 
combining DCE-MRI with a new Gd-based blood pool contrast agent [30]. 
 
 
Material and methods 
GIST cell lines culture and MRI image analysis are described in the Supplementary Methods. 
Mice 
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Male 7-week-old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ(NSG) mice with an average body weight of 
30g were used. All animals were housed in sterile cages under laminar flow hoods in a 
temperature controlled room with a 12-hour light/12-hour dark schedule and fed with 
autoclaved chow and water ad libitum. Mice were maintained at the animal facility of the 
Molecular Biotechnology and Health Sciences department at University of Turin and treated 
in accordance with University Ethical Committee and European guidelines (Directive 
2010/63) under the protocol number 0081521. 
Heterotopic GIST xenografts were generated by subcutaneous bilateral injection of GIST882, 
GIST430 and GIST-T1 cell lines. For each cell line, n=8 mice have been bilaterally 
inoculated. GIST cells were suspended in 50 µl of Phosphate Buffered saline (PBS) mixed 
with 50 µl of Matrigel™ Matrix (BD Pharmigen, Milano, Italy) at a density of 2x106, 1x106 and 
2,5x104 for GIST882, GIST430 and GIST-T1, respectively. Tumor growths were weekly 
monitored over time by using a caliper and tumor volumes calculated by [(length x width2)/2]. 
 
In vivo imaging experiments 
T2-weighted (T2w) MRI anatomical acquisitions have been weekly performed and tumor 
volumes calculated on images by drawing a region of interest (ROI) for both tumors using 
ITK-SNAP software (http://www.itksnap.org/pmwiki/pmwiki.php). 
When tumors reached a volume in the range of 30-500 mm3, DCE-MRI experiments were 
performed. Mice were anesthetized by injecting a mixture of tiletamine/zolazepam (Zoletil 
100; Virbac, Milan, Italy) 20 mg/kg and xylazine (Rompun; Bayer, Milan, Italy) 5 mg/kg and a 
27-gauge catheter was introduced into the tail veins for contrast agent (CA) injection. MR 
images were acquired with a 1 Tesla Aspect M2 MRI System (Aspect Magnet Technologies 
Ltd., Netanya, Israel). T2w anatomical images were acquired for monitoring tumor progression 
with a Fast Spin Echo sequence (TR = 2500 s; TE = 44ms; number of slices = 10; slice 
thickness = 1.5 mm; FOV = 40 mm; matrix = 152 × 160; NEX = 4; acquisition time = 3 m 20 
s). 
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DCE-MRI dynamic protocol consisted of an axial T1w 3D spoiled Gradient Echo sequence 
with 3 initial pre-contrast images acquisition followed by the injection of a gadolinium binding 
serum albumin CA (Gd-AAZTA-MADEC, CAGE Chemicals, Novara, Italy) through the 
catheter. After injection at a dose of 0.03 mmol Gd/kg b.w., 37 dynamic post-contrast images 
were acquired with the following parameters: TR = 40; TE = 2.1msec, flip angle = 60°, 
number of slices = 10, slice thickness = 1.5 mm, FOV = 40 mm, matrix = 128 × 128. 
 
Immunofluorescence staining 
After MRI acquisition, 0.25 mg Dextran-Texas red 40 kD (Life Technologies, Monza, Italy) 
was intravenously injected in mice to assess vessels leakage. Ten minutes later, mice were 
sacrificed, tumors excised and embedded in Optimal Cutting Temperature matrix compound 
(Tissue-Tek® OCT™) for cryosection staining and preserved at -80°C. Texas Red-
conjugated Dextran signal was amplified with polyclonal rabbit anti-Texas Red® (Life 
Technologies, Monza, Italy). MVD was assessed by CD31 staining (monoclonal rat anti-
CD31, BD Pharmigen, Milano, Italy). All secondary antibodies are purchased from Life 
Technologies (Alexa-Fluor®, Monza, Italy). Briefly, slices were incubated with 10% goat 
serum for 1 hour at room temperature (RT) and then with primary antibodies (dilution 1:200) 
overnight at 4 °C. After washing in PBS-Tween 0.1%, slices were incubated with secondary 
antibody (dilution 1:500) for 1 hour RT. Nuclei were stained with DAPI (Sigma Aldrich, 
Milano,Italy) and slices rinsed with bidistilled water. 
 
Evaluation of MVD and MDD 
Immunohistochemical assessment was performed using an ApoTome fluorescent 
microscope (Zeiss, Germany). The degree of angiogenesis was determined by calculating 
the microvessel density (MVD) on CD31 positive slices and the extravasation of dextran as 
mean dextran density (MDD). Microvessels were visualized as lumen-containing structures in 
which all single cells or cluster of cells are positive for CD31 immunereaction. Staining for 
CD31 was visualized as a green signal (wavelength 488 nm, FITC green), whereas dextran 
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extravasation emits in red (wavelength 568 nm, Texas red). The entire section was 
systematically scanned at x100 magnification, ten fields were viewed at x200 magnification 
and images of CD31, dextran and DAPI (wavelength 461 nm, blue) staining were taken. Two 
or more positive foci belonging to the same continuous vessel were counted as one 
microvessel, as described by Weidner et al. [31]. The MVD and MDD were manually counted 
and averaged over ten fields. 
 
Western blot samples and analysis 
Cells from GIST 430-, 882- and T1-derived  tumors were extracted with RIPA buffer (1% 
Triton X-100, 0,1% SDS, 1% sodium deoxycholate, 150 mM NaCl, 50 mM Tris-HCl pH 7, 0.4 
mM Na3VO4, inhibitor mix). Cell lysates were centrifuged at 13,000 g for 10 minutes and the 
supernatants were collected and assayed for protein concentration with the Bio-Rad protein 
assay method (Biorad, Hercules, CA, USA). Total cell lysates were separated by SDS-PAGE 
under reducing conditions, transferred to nitrocellulose and immunoblotted overnight with 
primary antibodies against Vinculin (loading control), VEGFR2 and VEGFR3 at 4 °C. Mouse 
monoclonal antibody against Vinculin was produced at Molecular Biotechnology Center 
(MBC), while antibodies against VEGFR2 and VEGFR3 were purchased from Cell Signaling 
(Beverly, MA,USA). Blots were incubated with mouse or rabbit horseradish-peroxidase 
conjugated secondary antibodies for 1 h at room temperature. ECL (Euroclone) was used to 
detect chemoluminescent signals. Protein band intensities were measured by a scanning 
densitometer (Quantity One; PDI Inc, New York, USA).  
 
Statistical analysis 
Statistical analysis of imaging data, microvessels counting and western blot densitometry 
was performed using GraphPad Prism 5 software (GraphPadInc, San Diego, California, 
USA). All data are shown as mean ± SEM. One-way ANOVA analysis and Dunn’s multiple 
comparison tests were used to compare the functional mean MRI-based estimates values 
obtained in GIST882, -T1 and 430.  
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One-way ANOVA analysis and Bonferroni multiple comparison tests were performed to 
evaluate statistical MVD and MDD differences among GIST tumors. The relationship 
between the ex-vivo histological markers of vascularization MVD/MDD and the estimates 
obtained by DCE-MRI analysis (Ktrans and vp) have been assessed with parametric Pearson’s 
rank correlation (r). For all tests, a P-value <.05 was considered statistically significant. 
 
Results 
Generation of imatinib-sensitive and resistant GIST models on NSG mice 
GIST882, GIST -T1 and GIST430 cell lines have been subcutaneously inoculated in NSG 
mice to generate imatinib-sensitive and resistant GIST models. Solid tumors efficiently 
developed in all the animals considered for the study, exhibiting different kinetic growth 
related to the inoculated GIST cell lines (Fig. 1a). Palpable masses are typically detected 
from 15 to 18 days after inoculation. GIST-T1 tumors display fast growth rate, similarly to 
GIST430. Conversely, tumor growth is much slower in GIST882, reaching a maximum of 400 
mm3 after 45 days from inoculation. Mouse models exhibit different morphological features. 
Coronal T2w MRI images highlight highly hemorragical and bleeding lesions in GIST-T1 
tumors (Fig. 1b), partially similar to what observed for GIST430 tumors. Conversely, 
GIST882 tumors exhibit dense and compact tissue, with no signs of bleedings. Biopsies and 
histological H&O results showed substantial morphological differences among GIST models, 
confirming MRI findings. Cellular and subcellular structures identified by H&O staining are in 
accordance with those previously reported elsewhere, for all three GIST tumors [32, 33]. 
Different KIT expression levels among GIST-T1, 882 and 430 tumors were found by Western 
Blot analysis (Fig. 1c). 
 
DCE-MRI identifies differences in vascularization and permeability between imatinib-
sensitive and resistant GIST tumors 
Functional MRI acquisitions were performed on GIST tumors with volumes in the range of 
30-500 mm3. Tumor microvessels permeability (Ktrans) and plasmatic volume (vp) values have 
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been calculated by applying a two-compartments pharmacokinetic model on DCE-MR 
images following the administration of Gd-AAZTA-MADEC, a new blood-pool contrast agent 
(Figure 2a). Imatinib-resistant GIST430 tumors exhibit significantly higher Ktrans mean values 
compared to imatinib-sensitive GIST882 and -T1 (38.1±7.4 E-5 for GIST-430, 14.9±2.2 E-5 
for GIST882 and 9.8±2.0 E-5 for GIST-T1, P=.0002, 1-way ANOVA). A similar trend was 
observed for vp, whose values are significantly higher in the imatinib-resistant tumors 
compared to sensitive ones (0.10±0.01 for GIST430, 0.04±0.004 for GIST882 and 
0.02±0.004 for GIST-T1; P<.0001, 1-way ANOVA). Imatinib-sensitive tumors (GIST882 and -
T1) show similar mean values for both estimates, without any significant difference. 
Representative parametric maps of Ktrans and vp are overlaid on T2-weighted anatomical 
images and displayed in Fig 2b. Qualitatively, these maps illustrate a substantial increase in 
Ktrans and vp values in GIST430 tumors in comparison to GIST882 and GIST-T1. 
 
Ex vivo evaluation of tumor angiogenesis correlates with MRI quantitative parameters 
Ex-vivo staining for CD31 and dextran was performed to evaluate GIST vascularization and 
permeability, respectively. Quantitative analysis demonstrated that GIST430 tumors are 
highly vascularized, with mean MVD=31.9 ±4.6 (Fig. 3a). Conversely, imatinib-sensitive GIST 
tumors display lower MVD (MVD= 18.0 ±0.9 for GIST 882, MVD=4.9 ±0.6 for GIST-T1). One-
way ANOVA analysis shows significant difference in MVD mean values between GIST430 
towards GIST-T1 and GIST882 tumors (P=.0002). Representative immunofluorescence 
images of GIST-T1, 882 and 430 show different vascularization levels in GIST-T1, 882 and 
430 tumor sections (Fig. 3b). Interestingly, MVD show a strong positive correlation with both 
DCE-MRI estimates vp (P<.0001, r=0.82) and Ktrans (P=.002, r=0.78) (Fig. 3c). The 
extravasation of dextran was assessed to evaluate functional vessel permeability ex-vivo as 
mean dextran density (MDD, Figure 4a). MDD is more than three-times higher in GIST430 
(15.7±2.6) than in GIST882 and -T1 (2.7±0.3 for GIST882 and 3.4±0.3 for GIST-T1), with 
statistical significance (P=.0003, Fig 4a). Representative images of dextran-Texas red 
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extravasation and CD31-positive vessels are shown in fig 4b. Strong positive correlation is 
found between MDD and Ktrans (P=.006, r=0.77) and MDD and vp (P=.0001, r=0.94, Fig. 4c). 
Expression of endothelial receptors involved in tumor angiogenesis (VEGFR2) and 
lymphoangiogenesis (VEGFR3) was investigated by western blot analysis in GIST tumors as 
additional markers of tumor angiogenesis (Fig. 5a-b). Both VEGFR2 and VEGFR3 display a 
greater than three-fold increase in terms of expression level in GIST430 compared to GIST-
T1 and 882 (P=.0015 for VEGFR2, P=.0007 for VEGFR3). 
 
Discussion 
The aim of our work was to evaluate the ability of a functional MRI-based approaches to 
highlight differences in tumor microenvironment properties related to imatinib resistance in 
GIST murine models. For this purpose, GIST tumor vascularization was investigated by a 
DCE-MRI approach. Our findings demonstrated that DCE-derived pharmacokinetic 
parameters can detect differences in plasmatic volume and permeability among the 
investigated GIST tumor cell lines. In particular, higher Ktrans and vp values were measured for 
the imatinib-resistant tumors (GIST430), compared to both imatinib-sensitive ones (GIST-T1 
and GIST882). This study indicates that the characterization of tumor microenvironment and 
vasculature properties of GIST tumors by a functional MRI-based approach can discriminate 
between imatinib-responsive and -resistant tumors. 
Angiogenesis is one of the fundamental steps for the progression and metastasis of solid 
tumors. Clinical implications of angiogenesis and its prognostic significance have been 
reported in several cancers, also in lesions of the gastrointestinal tract [34-37]. Despite this, 
the risk of recurrence or the metastatic potential in GIST is commonly predicted by the 
Fletcher classification system, mainly based on the evaluation of anatomical criteria. Only 
recently, several factors involved in the angiogenesis process have been proposed as 
additional predictive biomarkers of GIST transition from benign to malignant lesions. Ex-vivo 
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studies on GIST specimens showed that MVD is closely related to VEGF expression and 
strongly associated with GIST with poorer prognosis. These data pointed out that 
angiogenesis and vascularization are associated with tumor grade, mitotic count and higher 
risk of metastasis in GIST [15, 16]. Further confirming the key role that angiogenesis plays in 
GIST pathogenesis, we show that imatinib-sensitive and -resistant tumors have different 
vascularization properties by exploiting a DCE-MRI approach.  
In particular, GIST430 tumors exhibit more than two-fold higher Ktrans and vp values if 
compared to imatinib-sensitive tumors, with statistical significance. DCE-MRI results 
identified a more unstructured and deregulated vasculature in terms of blood flow and 
permeability (Ktrans) and vascular density (vp), properties linked to the angiogenic process. 
Moreover, our in vivo functional findings are validated by histological quantification of 
endothelial vessels (CD31) and permeability (dextran). Both parameters confirmed higher 
vascularization and permeability in GIST430 tumor sections, compared to GIST-T1 and 882 
ones. These findings are in accordance with recent data showed by Imamura et al [13], 
where higher expression of VEGF and increased MVD were found in GIST tumor harboring 
KIT mutation associated with resistance to imatinib. However, so far little is known about the 
association between angiogenesis and imatinib resistance in GIST. To the best of our 
knowledge, this is the first study that investigated tumor vascularization properties in several 
GIST metastatic murine models and detected functional differences in imatinib-resistant and 
-sensitive tumors by exploiting the in vivo DCE-MRI approach. Interestingly, a significant 
positive correlation was found between vp and MVD. The higher vp observed in the imatinib-
resistant tumors indicates a larger vascular space; this result is confirmed by the higher MVD 
values in GIST430, suggesting that vp can be used as a marker of vessel density. In 
particular, considering the role of MVD in GIST prognosis, we could hypothesize that vp could 
be used to assess in vivo the GIST aggressiveness. GIST882 showed significantly higher 
MVD in comparison to GIST-T1, whereas any difference is detected by DCE-MRI. We can 
explain this mismatch considering that Ktrans and vp estimates assess only functional vessels, 
whereas MVD assesses vessels independently of their functionality. Consequently, DCE-
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MRI can detect poor perfusion properties of GIST882 tumors despite the presence of a 
relatively high vessel density. 
Moreover, Yamashita et al.[38] observed in vivo intratumoral vessels in GIST patients with 
worst prognosis by contrast-enhanced ultrasound technique. The visualization of intratumoral 
vessels correlated with VEGF expression, highlighting the relationship between angiogenesis 
and malignancy in GIST. Interestingly, we observed increased expression of VEGFR2 and 
VEGFR3 in GIST430 tumors in comparison to GIST882 and GIST-T1. VEGFR2 plays a well-
known role in tumor angiogenesis formation and sprouting, whereas VEGFR3 is mainly 
involved in the lymphoangiogenesis process. Lymphoangiogenesis promotes and sustains 
tumor progression and angiogenesis and favors the metastases spread-out through the 
surrounding lymphatic networks. Several studies indicate that VEGFR3 is usually highly 
expressed in the most aggressive human cancers [39-41]. Our findings suggest that, in 
addition to VEGFR2, VEGFR3 expression may be relevant for GIST imatinib-resistant tumor 
growth and the direct targeting of these receptors could be promising in non-responding 
GIST tumors.  
Second and third lines of GIST therapeutic regimen following imatinib resistance consider 
antiangiogenic targeted therapies as a key factor for alternative treatment options. Sunitinib 
is a multityrosine kinase inhibitor that is clinically approved for the treatment of imatinib-
resistant GIST [42]. In addition to KIT and PDGFR, sunitinib targets also VEGFR1 and 
VEGFR2 receptors. Recently, Kim et al. [43] reported in a pilot clinical study that the effect of 
sunitinib treatment in GIST patients can be quantitatively monitored by DCE-MRI. In 
particular, they observed significant reduction in Ktrans values upon therapy that can be 
explained by the reduced wash-in rate following vessel density reduction. Their study, 
although limited to few patients, showed that the DCE-MRI technique can detect vascular 
functional changes in treated GIST and that it can be exploited as a valid alternative to 
conventional treatment assessment approaches. In addition, perfusion imaging studies 
based on contrast enhanced computed tomography demonstrated lower perfusion values in 
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good responders, whereas poor responders showed significant lower perfusion values [44, 
45]. Our study clearly demonstrated in GIST mouse models that imatinib-resistant tumors 
exhibit higher Ktrans and vp values compared to imatinib-sensitive ones. Therefore, changes in 
these functional properties can be non-invasively monitored by DCE-MRI to assess the 
efficacy of antiangiogenic treatments, both for sunitinib, as for other specific drugs that are 
currently in Phase II or III of clinical trials [46]. 
Several findings suggest that the evaluation of tumor neovascularity and associated 
permeability changes can be improved by using macromolecular Gd-based CA adducts, that 
can accumulate within the tumor owing to the enhanced permeability and retention effect 
[47]. The main advantages rely in a better assessment of the tumor vascularization 
properties in comparison to small molecular weight CAs, in combination with higher contrast 
efficiency at low-intermediate magnetic fields (0.5-1.5 T) [48-50]. Our results, obtained using 
a new Gd-based blood pool CA [30], demonstrate that accurate characterization of GIST 
tumor microvascular properties is feasible at low magnetic fields, hence facilitating 
translational purposes. 
This study presents some limitations. First, only GIST cell lines sensitive or resistant to 
imatinib have been investigated. Further studies are needed to extend the herein reported 
evidences to GIST cell lines sensitive or resistant to other TK inhibitors (e.g. sunitinib or 
regorafenib). Moreover, a small number of GIST cell lines have been investigated. Mice were 
inoculated with two imatinib-sensitive (GIST-T1 and GIST882) and one imatinib-resistant 
(GIST430) cell lines. Further evaluations on additional GIST cell lines and on patient-derived 
tumors could extend the proposed MRI approaches for characterizing GIST tumors and for 
assessing novel TK inhibitors [51, 52]. However, GIST-T1, GIST882 and GIST430 cells are 
the most used and well characterized GIST cell lines, and commonly considered 
representative of imatinib-sensitive and resistant tumors. An additional limitation relies on the 
fact that clinical trials are needed to confirm DCE-MRI as a valuable tool in assessing GIST 
tumor treatment response. 
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In conclusion, our work highlights the important role that functional MRI approaches can 
provide to detect functional differences between imatinib-sensitive and -resistant GIST 
tumors. In particular, changes in microvessel permeability and density among GIST tumors 
are pointed out by our DCE-MRI approach. Imatinib-resistant tumors exhibit increased Ktrans 
and vp values compared to imatinib-sensitive ones, as confirmed by ex-vivo quantification of 
MVD and MDD in GIST430 tumor sections. In addition, strong positive correlation was found 
between MRI and histological estimates. The current study suggests that the assessment of 
angiogenesis could be considered as a new promising biomarker of response to imatinib 
treatment. For this purpose, DCE-MRI deserves more attention at clinical level for the non-
invasive assessment of treatment response by evaluating tumor vascularization properties. 
In view of the few therapeutic options that are currently available for imatinib-resistant 
patients, angiogenesis targeting may be an effective therapeutic strategy for GIST patients 
and functional MRI approaches may provide earlier detection of tumor response evaluation in 
alternative to conventional imaging modalities. 
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Fig.1 Implementation of GIST-T1, 882 and 430 tumor models in NSG mice. (a) Curves 
indicates tumor growth diameter (mm) measured by a caliber after 14, 21, 28, 35 and 42 
days after bilateral, subcutaneous inoculation of GIST cell lines (2.5·104, 2.0·106 and 1.0·106 
cells for GIST-T1, GIST882 and GIST430, respectively) in NSG mice (n=10 for each cell 
line). Tumors growth was detected at 21 days post inoculation. GIST-T1 and GIST430 exhibit 
faster kinetic growth rate in comparison to GIST882. (b) Morphological characterization of 
GIST tumors. Left panel: coronal T2w MRI images acquired at 7T Bruker scanner of GIST-T1 
(top), GIST882 (middle) and GIST430 (bottom) tumors (arrowhead). Presence of 
hemorragical bleedings are clearly shown in GIST-T1 tumors. Middle panel: representative 
biopsies of excised GIST-T1 (top), GIST882 (middle) and GIST430 (bottom) tumors of mice 
sacrificed after MRI acquisition. The arrowheads indicate the extensive bleeding in GIST-T1 
tumors. Right panel: representative H&O staining of tumor sections belonging to GIST-T1 
(top), GIST882 (middle) and GIST430 (bottom) mice acquired using an optical microscope 
with an objective 20 X. (c) Western blot analysis indicates increase expression of KIT 
receptor in GIST430 compared to GIST-T1 and GIST882. Vinculin is provided as loading 
control. Densitometric analysis of protein levels in at least three independent experiments is 
shown.  Statistical analysis was performed by Student's t-test (*P<.05, ** P<.01) 
Fig.2 Functional MRI estimates indicate higher vessel density and permeability in GIST430 
imatinib-resistant tumors, whereas GIST882 exhibit decreased cellularity. (a) Bar graphs 
show mean values of Ktrans (min-1, left) and vp (right) obtained by DCE-MRI for imatinib-
sensitive GIST-T1 (black) and GIST882 (grey) and imatinib-resistant GIST430 tumors 
(white). GIST430 tumors display significant increase of Ktrans and vp in comparison to GIST-
T1 and GIST882. Imatinib-sensitive tumors show comparable mean values for both Ktrans and 
vp. Values are shown as mean ± SEM. Statistical significance with: **P<.01; ***P<.001. (b) 
Representative parametric maps of Ktrans and vp overimposed on related T2w anatomical 
images. GIST-T1 (left), GIST882 (middle) and GIST430 (right) show different values of Ktrans 
(fist line) and vp (second line). Parametric maps highlight increased values of the 
pharmacokinetic parameters in GIST430 in comparison to GIST-T1 and GIST882 tumors.(c) 
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ADC values obtained by DW-MRI analysis. Bar graphs indicate decreased ADC (mm2/sec) 
values for GIST882 in comparison to GIST-T1 and GIST430, with statistical difference with 
GIST-T1. Values are shown as mean ± SEM. Statistical significance with: *P<.05 
Fig.3 Ex-vivo analysis confirms MRI findings by evaluating vascular density in GIST tumors. 
(a) Bar graph indicates microvessel density (MVD) calculated as number of vessels in GIST-
T1 (black), GIST882 (grey) and GIST430 (white) tumor sections. Vessels are immune-
stained for the endothelial marker CD31. GIST430 tumors show increased MVD in 
comparison to both GIST-T1 and GIST882 tumors sections, with statistical significant 
difference. Significant difference is also observed between GIST-T1 and GIST882 MVD. 
Values are shown as mean ± SEM. Statistical significance with: *P<.05; ***P<.001. (b) 
Representative immunofluorescence staining for CD31 (red) in GIST-T1 (left), GIST882 
(middle) and GIST430 (right) tumor sections. Nuclei are counterstained by Hoechst (blue). 
Images were acquired by using a fluorescence microscopy with an objective 20 X. GIST430 
section shows increased vessel density in comparison to GIST-T1 and GIST882 ones. (c) 
Correlation between MRI estimates Ktrans (left) and vp (right) and histological MVD. Strong 
positive correlation is observed between both MRI estimates and their related MVD values 
(vp: P<.0001, r=0.82; Ktrans: P=.002, r=0.78) 
Fig.4 Increased vessels permeability in GIST430 tumors is confirmed by Dextran-Texas red 
extravasation. (a) Bar graphs indicate mean dextran density (MDD) calculated as 
extravasation of Dextran-Texas red in positive-CD31 immune-stained vessels. GIST430 
display significant higher dextran extravasation in comparison to GIST882 and GIST-T1. 
Values are shown as mean ± SEM. Statistical significance with: ***P<.001. Dextran-Texas 
red was tail vein injected and mice were sacrificed 10 minutes later. (b) Representative 
images of CD31 (green), Dextran-Texas red extravasation (red) in GIST-T1 (first line), 
GIST882 (second line) and GIST 430 (third line) tumor sections. Images were obtained using 
a fluorescence microscopy with an objective 40X. Merge images are counterstained with 
Hoechst (blue). (c) Correlation between MRI estimates Ktrans (left) and vp (right) and 
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histological MDD. Strong positive correlation is observed between both MRI estimates and 
their related MDD values (vp: P=.0001, r=0.94; Ktrans: P=.006, r=0.77). 
Fig.5 Western Blot analysis (a) and related bar graphs (b) of VEGFR2 and VEGFR3 of 
GIST-T1, GIST882 and GIST430 tumor samples. GIST430 tumors reveal significantly higher 
expression of both receptors in comparison to GIST-T1 and GIST882 ones. Values are 
shown as mean ± SEM. Statistical significance with: *P<.05 
 
